RiaGev™ is a proprietary compound that has been shown to enter the pathway directly and more efficiently increase NAD+.

A third party pharmacodynamics study has demonstrated that RiaGev enters the NAD biosynthetic pathway directly and increases NAD+ efficiently throughout the body, including muscle and brain.

American Preclinical Services, Minneapolis, MN; Alex Xue, PhD. Bioenergy Life Science, Inc., Minneapolis, MN.

Introduction: Nicotinamide adenine dinucleotide (NAD) is a co-factor in several biological processes and is a crucial element for life and every day health. Levels of NAD in the body decrease with age and obesity. Evidence accumulated in the last decade have demonstrated that decreased levels of NAD are correlated with health issues including cognitive decline, neurological disorder, mitochondrial dysfunction, metabolic imbalance and possibly a shorted healthy lifespan [1,2].

Study Design: The test animals were grouped into 6 groups, each supplemented with a test article, including Water, Nicotinamide (108mg/kg), 100mg/kg RiaGev, 300mg/kg RiaGev, 900mg/kg RiaGev, or 2700mg/kg RiaGev. A test article is gavaged to the animal twice daily starting Day 0 to Day 4. The first dose is given at 8 a.m. and second dose at 5 p.m. each day. Blood samples were collected from each animal at 6 p.m. and immediately extracted and analyzed afterward in the evening. At the end of the 5th day, animals are anaesthetized and their tissues, including brain, muscle, and liver, were harvested for analyses. The analyses were conducted using LC-MS following established protocol, with internal standard compounds for quantification. The compounds tested included NAD, nicotinamide mononucleotide (NMN), and nicotinamide riboside (NR).

Results and Conclusion:

1. Time course of RiaGev NAD-boosting action. NAD metabolites increased steadily after oral supplementation of RiaGev in dose dependent manner (Figure 1), similar to oral supplementation of nicotinamide riboside.

2. Tissue Distribution of RiaGev. RiaGev-derived NAD tissue distribution and dose response of RiaGev increased NAD in liver, muscle, and brain (Figure 2).

3. For the tissues analyzed, liver contains the highest concentration of NAD, followed by brain and muscle.

4. The results demonstrated that RiaGev effectively and efficiently increased NAD levels throughout the body, including liver, muscle, and brain. Increased levels of NAD in the organs suggest that RiaGev will be beneficial in neurological and muscular functionalities as well as to overall health. Additional research will be conducted to further demonstrate this conclusion.

References:

1. Zhang M, Ying W. (2018) NAD Deficiency Is a Common Central Pathological Factor of a Number of Diseases and Aging: Mechanisms and Therapeutic Implications. Antioxid Redox Signal. 2018 Feb 7. doi: 10.1089/ars.2017.7445.

2. Yamada K, Hara N, Shibata T, Osago H, Tsuchiya M (2006) The simultaneous measurement of nicotinamide adenine dinucleotide and related compounds by liquid chromatography/electrospray ionization tandem mass spectrometry. Anal Biochem 352:282–285.

 

Download Full Study